Related Experiment Video
Updated: May 5, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
7.6K
Pioglitazone--do we really need it to manage type 2 diabetes?
1AMRI Hospitals Salt Lake, Kolkata, India.
Diabetes & Metabolic Syndrome
|December 3, 2013
Summary
With newer diabetes medications available, this review questions the continued use of pioglitazone due to its controversies and side effects. Newer agents offer better glucose control and fewer risks.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetology
Background:
- Several diabetes medications have been withdrawn from the market due to safety concerns.
- Pioglitazone, a thiazolidinedione, improves insulin sensitivity but faces controversies including weight gain, fractures, and bladder cancer risks.
Purpose of the Study:
- To critically evaluate the role of pioglitazone in diabetes management.
- To compare pioglitazone with newer antidiabetic agents, considering their efficacy and safety profiles.
Main Methods:
- Review of existing literature on pioglitazone and newer antidiabetic drug classes.
- Analysis of clinical trial data and post-marketing surveillance reports.
- Comparative assessment of metabolic and extra-glycemic benefits.
Main Results:
- Pioglitazone's benefits in insulin sensitivity and potential cardioprotection are weighed against significant safety concerns.
- Newer agents like DPP-4 inhibitors, GLP-1 analogues, and SGLT-2 inhibitors offer effective glucose lowering with favorable profiles regarding hypoglycemia and weight gain.
- Emerging evidence suggests these newer agents may present a safer alternative to pioglitazone.
Conclusions:
- The advent of newer antidiabetic agents with improved safety and efficacy profiles challenges the continued use of controversial drugs like pioglitazone.
- A careful risk-benefit assessment is crucial when selecting pharmacotherapy for diabetes management.
- Further research is needed to fully elucidate the long-term safety and efficacy of all available antidiabetic agents.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
998
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:22Diabetes Mellitus: Type 2 and Gestational
5.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K